LOS ANGELES, CA - November 12, 2025 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology.
HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain actionable heart intelligence outside of a medical facility. The company’s intellectual-property foundation is a major reason for its placement, with over 20 issued patents related to technology enablement.
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead ECG acquired from 5 electrodes. It is intended for use by adult patients in clinical settings or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care, redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software is under FDA review.
This recognition as a top global innovator validates HeartBeam’s approach to remote cardiac monitoring and positions the company as a key player in the evolving landscape of portable ECG diagnostics. The implications for patients include improved access to advanced cardiac monitoring outside traditional clinical settings, potentially leading to earlier detection of cardiac issues and more timely interventions.
